Form 8-K Amphastar Pharmaceutical For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Amphastar Pharmaceuticals (AMPH) PT Raised to $25 at Needham & Company
November 9, 2018 9:14 AM ESTNeedham & Company analyst Serge Belanger raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $25.00 (from $20.00) while maintaining a Buy rating.
Belanger commented, "AMPH delivered 3Q18 results that beat both top- and bottom-line Street consensus estimates, benefiting from a surprisising significant uptick in... More
